Yue Wu is the CEO of Shanghai Biogenuinetech Co., Ltd. He graduated from Dalian Medical University and has published five SCI papers, which have been cited 134 times. His research primarily focuses on utilizing multi-omics at the single-cell level to investigate the mechanisms behind the occurrence and development of biological systems and clinical diseases. By integrating genomics, epigenetics, metabolic reprogramming, and proteomics with various methodologies such as virtual screening, molecular docking, molecular dynamics, and validation in model organisms, he aims to empower the development of targeted therapeutics for diseases.
Yue Wu is the CEO of Shanghai Biogenuinetech Co., Ltd. He graduated from Dalian Medical University and has published five SCI papers, which have been cited 134 times. His research primarily focuses on utilizing multi-omics at the single-cell level to investigate the mechanisms behind the occurrence and development of biological systems and clinical diseases. By integrating genomics, epigenetics, metabolic reprogramming, and proteomics with various methodologies such as virtual screening, molecular docking, molecular dynamics, and validation in model organisms, he aims to empower the development of targeted therapeutics for diseases.